SSRI and Bone Metabolism in HIV+ Patients with Antiretroviral Therapy

Authors

  • Martín J. Mazzoglio y Nabar Médico especialista en Psiquiatría; Servicio Penitenciario Federal, Ministerio de Justicia y Derechos Humanos; Docente Adscripto de la Facultad de Medicina, UBA; Miembro Titular e Integrante de los Capítulos Neurociencia y Psiquiatras en Formación (PEF), Asociación de Psiquiatras Argentinos (APSA), CABA, Argentina
  • Milagros María Muñiz Médica especialista en Psiquiatría; Ministerio de Seguridad; Miembro Titular e Integrante del Capítulo Psiquiatras en Formación (PEF), Asociación de Psiquiatras Argentinos (APSA), CABA, Argentina
  • Alexis A. Mejías Delamano Médico especialista en Medicina Farmacéutica, UBA; Residente de Psiquiatría, Hospital General de Agudos Manuel Belgrano; Docente Auxiliar de Farmacología, Facultad de Medicina, UBA; Integrante del Capítulo Psiquiatras en Formación (PEF), Asociación de Psiquiatras Argentinos (APSA), CABA, Argentina
  • Santiago Muñoz Médico Residente de Psiquiatría, Hospital General de Agudos Manuel Belgrano; Docente Auxiliar de Farmacología, Facultad de Medicina, UBA; Integrante del Capítulo Psiquiatras en Formación (PEF), Asociación de Psiquiatras Argentinos (APSA), CABA, Argentina
  • Nahuel Magrath Guimet Médico Residente de Psiquiatría, Hospital General de Agudos Manuel Belgrano; Docente Auxiliar de Farmacología, Facultad de Medicina, UBA; Integrante del Capítulo Psiquiatras en Formación (PEF), Asociación de Psiquiatras Argentinos (APSA), CABA, Argentina

Keywords:

antidepresivos ISRS, densidad mineral ósea, antirretrovirales

Abstract

We report a series of 9 male HIV + patients, average age of 41.2 years, viral load negative (<50 copies RNA/ml), treated with antiretroviral (nucleoside and non-nucleoside inhibitors of reverse transcriptase) without systemic infections, the CNS diseases or marker or corticoidoterapia in progress. Were evaluated and supported by their infectologists interconsultation during the period October 2008-October 2013 by depressive syndrome. Psychotherapeutic and psychiatric treatment was initiated with SSRIs and clonazepam; Neuroimaging control and biochemical laboratory studies at baseline and 2 months of treatment were conducted. In the course of psychopharmacological treatment not suffer fractures due to falls and alterations were detected in bone metabolism markers and images. He studied with endocrinology and interdisciplinary medical clinic, decided to withdraw the SSRIs with normalization of biochemical values and psychotherapeutic treatment was continued. We will raise the associations between the use of SSRIs, disturbances of bone metabolism with clinical correlation and possible drug interactions between antidepressants and antiretroviral.

Downloads

Download data is not yet available.

Published

2015-07-10

How to Cite

Mazzoglio y Nabar, M. J., Muñiz, M. M., Mejías Delamano, A. A., Muñoz, S., & Magrath Guimet, N. (2015). SSRI and Bone Metabolism in HIV+ Patients with Antiretroviral Therapy. Vertex Revista Argentina De Psiquiatría, 26(121, mayo- jun.), 202–210. Retrieved from https://revistavertex.com.ar/ojs/index.php/vertex/article/view/1073

Most read articles by the same author(s)